Search for a trial

COVID-19 Primary care Platform for Early treatment and Recovery (COPPER) Study: an open-label randomized controlled trial

To evaluate the (cost)effectiveness and safety of early dexamethasone treatment in preventing hospital admission or death and reducing disease severity in patients who are monitored after a GP consultation for deteriorating COVID-19. Because the…

COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older.

Objectives for the Randomized Observe-Blinded Phase:Primary Objectives:Primary Efficacy Objective• To demonstrate the efficacy of a 2-dose schedule of CVnCoV in the prevention of first episodes of virologically-confirmed cases of COVID-19 of any…

SARS-CoV2 vaccination and activation of the coagulation system

To explore the change in circulating biomarkers of activation of the coagulation system before and after SARS-CoV2 vaccination (AstraZeneca).

Effect of Iodine treatment in patiënts with COVID-19 disease.

Demonstrate that iodine treatment has a beneficial effect on the course of COVID-19 disease. Beneficial effect is defined as less critically relevant deterioration such as transfers from regular to intensive care units, fewer days of hospitalization…

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection

Primary ObjectiveThe primary objective is to evaluate superiority of pimodivir in combination with SOC treatment compared to placebo in combination with SOC treatment on Day 6, with respect to the clinical outcome on the hospital recovery scale.

A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants (study 201584, FLAIR)

Primary:To demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks compared to remaining on ABC/DTG/3TC (or DTG and an approved dual-NRTI scheme) over 48 weeks.Secondary:To…

A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Sustained Virologic Response in Chronic Hepatitis B Participants With and Without Nucleos(t)ide Therapy Who Have Received and Responded to GSK3228836 in a Previous Treatment Study

Efficacy: To describe long-term durability of sustained virologic response (SVR) as measured by time to loss of SVR in treatment naïve participants who achieved a complete responseEfficacy: To describe long-term durability of sustained virologic…

Lactoferrin in the treatment of Long COVID

To reduce fatigue symptoms with the use of a bovine lactoferrin supplement in patients suffering from Long COVID.

Do Angiotensin Receptor BLOCKers have beneficial effect on the disease course of COVID-19 infection in high risk or elderly patients in an early phase

Objective: To assess whether angiotensin receptor blocker (ARB) use is beneficial in the early phase of the disease, to prevent lung oedema and damage in high risk patients with a proven COVID-19 infection.

A phase 1b, randomized, double-blinded, placebo-controlled study of hydroxychloroquine in outpatient adults with COVID-19

This study is designed to assess the antiviral activity of hydroxychloroquine in patients with SARS-CoV-2 virus. To evaluate the antiviral effects of hydroxychloroquine at the earliest stages of disease, the study will be conducted in outpatient…

COVID-19: ultra-Low Radiotherapy Dose1: Colorado-1 trial

To determine the pre-liminary efficacy of ultra-low dose radiotherapy for COVID-19 related pneumonia with respiratory insufficiency.

Convalescent Plasma Therapy from Recovered Patients to Treat COVID-19 Early in SARS-CoV-2 Disease

Primary objectivesTo evaluate the efficacy, feasibility, viro-immunological kinetics and safety following the administration of ConvP as a therapy for outpatients diagnosed with COVID-19 at increased risk for an unfavourable clinical outcome and…

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection with Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP)

Primary Objective• To evaluate the effect of EDP-938 on the progression of RSV infection by assessment of clinical symptomsSecondary Objectives• To evaluate the antiviral efficacy of EDP-938• To evaluate the pharmacokinetics (PK) of EDP-938• To…

A phase 1 single ascending dose study in healthy subjects to evaluate safety, tolerability, and pharmacokinetics of XVR011

In this study, we will investigate how safe the new compound XVR011 is and how well it is tolerated when it is used by healthy participants.We will also investigate how quickly and to what extent XVR011 is absorbed, transported, and eliminated from…

A randomized, double blinded clinical trial of convalescent plasma compared to standard plasma for treatment of hospitalized non-IC patients with COVID-19 infections

To evaluate the efficacy of convalescent plasma compared to standard plasma to improve an ordinal outcome as primary endpoint: consisting of shorter than the average of 6 days hospital stay, no admission to the intensive care unit (ICU), no need for…

Convalescent plasma from cured coronavirus disease (COVID) patients as a therapy for patients with severe COVID disease (CONCOVID)

PrimaryDecrease COVID-19 mortalitySecondary• Evaluate the effect of 300ml convP on hospital stay and the change in WHO disease severity score• Evaluate the effect of 300ml convP on mortality in patients admitted to the ICU • Evaluate the effect of…

Immunogenicity and safety study of a third measles mumps rubella (MMR-3) vaccine dose in healthy young adults in The Netherlands

Primary objective: * The main objective is to assess the effect of third dose of MMR (MMR-3) in young adults 18-25 years of age on the development and duration of mumps-specific serum virus neutralization (VN) and IgG antibody concentrations (…

Biocomparison study of crushed elbasvir/grazoprevir compared to the whole tablet (CRUSADE-2)/Hep-NED005

Primary objective:To assess pharmacokinetic similarity of EBR/GZR as a crushed (test) Zepatier tablet compared to a whole (reference) tablet.Secondary objective:To assess Cmax similarity of EBR/GZR as a crushed (test) Zepatier tablet compared to a…

Pharmacokinetics of a new paediatric formulation of valacyclovir used for prophylaxis and treatment of VZV and HSV infections in children (VALID II).

In this trial the plasma pharmacokinetics of acyclovir will be investigated after administration of valacyclovir oral solution in children who have an indication for (val)Acyclovir prophylactic treatment.Furhermore, the safety profile of a single…

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734*) in Participants with Severe COVID-19

The primary objective of this study is as follows: -To evaluate the efficacy of 2 remdesivir (RDV) regimens with respect to clinical status assessed by a 7-point ordinal scale on Day 14The secondary objective of this study is as follows: - To…